Abrocitinib ndi kamolekyu yapakamwa, yaing'ono, Janus kinase (JAK) 1 inhibitor mu chitukuko chochizira akuluakulu ndi achinyamata omwe ali ndi vuto la atopic dermatitis.

Abrocitinib akufufuzidwa mu mayesero a zachipatala NCT03796676 (JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis).

Panopa Abrocitinib ikupangidwa ndi Pfizer pofuna kuchiza atopic dermatitis (chikanga). Ndiwoyeserera wapakamwa kamodzi patsiku Janus kinase 1 (JAK1) inhibitor.

Atopic dermatitis (AD) ndi matenda apakhungu ovuta, osatha, otupa omwe amadziwika ndi pruritic, kuyabwa kwambiri, ndi zotupa za eczematous zomwe zimakhudza pafupifupi 25% ya ana ndi 2% mpaka 3% ya akulu padziko lonse lapansi. Abrocitinib ndi inhibitor yosankha ya Janus kinase-1 (JAK1) enzyme yomwe imalepheretsa kutupa. Chifukwa chake, tidafuna kuyesa mphamvu ndi chitetezo cha abrocitinib kwa AD yocheperako mpaka yowopsa.

Abrocitinib mu mlingo wa 100 mg kapena 200 mg ndi mankhwala othandiza, olekerera bwino, komanso odalirika pochiza odwala omwe ali ndi dermatitis ya atopic yolimbitsa thupi. Komabe, kusanthulako kunakomera mphamvu ya abrocitinib 200 mg pa 100 mg, koma zotsatira zoyipa monga nseru ndi mutu zimatha kuchitika kwambiri ndi 200 mg.